GILD Scores FDA Win for HDV Drug, CHMP Backs Trodelvy
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
Open original sourceLoading market dashboard
Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.
Open original source